Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 17/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512762 | 0.92 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10SMN1; SMN2GAA | |
| SCHEMBL7910494 | 0.89 | ALOX15 (0.39) | KDM4EALDH1A1HSD17B10SMN1; SMN2GAA | |
| SCHEMBL12756281 | 0.82 | MAPK1 (0.35) | KDM4EALDH1A1HSD17B10SMN1; SMN2GAA | |
| SCHEMBL20133945 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| Hydrochloric Acid SCHEMBL7910504 | 0.77 | ALDH1A1 (0.43) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| Hydrochloric Acid SCHEMBL7910402 | 0.77 | ALDH1A1 (0.43) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL300884 | 0.77 | CA12 (0.42) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL3867866 | 0.76 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10SMN1; SMN2GAA | |
| SCHEMBL1923453 | 0.75 | CA12 (0.38) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL16938405 | 0.75 | MAPT (0.54) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | STRATAGENE | 2005-01-06 | — | — | US | disclosed |
| WO-2004037989-A2 | MODIFIED NUCLEOTIDES AND METHODS OF LABELING NUCLEIC ACIDS | STRATAGENE (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | RNGTT, NT5C3B, NT5E | KDM4E 3798/4885ALDH1A1 2177/4885HSD17B10 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.